Walleye Capital LLC Mirati Therapeutics, Inc. Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $1.03 Million - $1.52 Million	24,413 New	24,413 $1.43 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $5.16 Million - $7.07 Million	-142,916 Reduced 78.32%	39,564 $1.43 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $5.13 Million - $7.62 Million	140,382 Added 333.46%	182,480 $6.78 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $1.74 Million - $4.15 Million	42,098 New	42,098 $1.91 Million
Q2 2022 Aug 08, 2022	SELL	$39.16 - $88.71 $105,379 - $238,718	-2,691 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $1.4 Million - $2.78 Million	-18,405 Reduced 87.24%	2,691 $221,000
Q4 2021 Mar 03, 2022	BUY	$132.01 - $190.29 $2.78 Million - $4.01 Million	21,096 New	21,096 $3.09 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $311,358 - $518,529	-4,462 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $315,731 - $574,973	4,462 New	4,462 $575,000
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $63,886 - $89,872	-820 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $48,781 - $85,862	820 New	820 $84,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.